Pentostatin

Sezary Syndrome, Graft-vs-Host Disease, Chronic Lymphocytic Leukemia + 4 more
Treatment
2 FDA approvals
20 Active Studies for Pentostatin

What is Pentostatin

PentostatinThe Generic name of this drug
Treatment SummaryAdenosine deaminase inhibitors are powerful drugs used to treat certain types of cancer, particularly hairy-cell leukemia. They can also be used in combination with other cancer treatments, and have the ability to suppress the immune system.
Pentostatinis the brand name
image of different drug pills on a surface
Pentostatin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Pentostatin
Pentostatin
2007
3

Approved as Treatment by the FDA

Pentostatin, also called Pentostatin, is approved by the FDA for 2 uses including Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia .
Hairy Cell Leukemia (HCL)
Hairy Cell Leukemia

Effectiveness

How Pentostatin Affects PatientsPentostatin is a drug used to treat certain types of leukemia, such as acute nonlymphocytic leukemia and hairy cell leukemia. It works by fooling the body into thinking it is a natural building block of DNA, like purine or pyrimidine, but then prevents the body from using it to make DNA. Once inside the cells, it gets incorporated into the DNA and RNA, disrupting the cell cycle and causing the cells to die.
How Pentostatin works in the bodyPentostatin is an inhibitor of adenosine deaminase, a molecule found in high amounts in T-cell lymphocytes. By blocking the breakdown of adenosine and deoxyadenosine, Pentostatin causes an increase in dATP levels which blocks DNA synthesis. It also gets incorporated into DNA and RNA which stops the cell from reproducing and kills it. This effect is specific to cells in the S-phase.

When to interrupt dosage

The suggested portion of Pentostatin is contingent upon the identified condition, for example Hairy Cell Leukemia, Prolymphocytic Leukemia and Chronic Lymphocytic Leukemia. The measure of dosage fluctuates in light of the method of administration indicated in the table beneath.
Condition
Dosage
Administration
Graft-vs-Host Disease
, 10.0 mg, 2.0 mg/mL, 10.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution
Sezary Syndrome
, 10.0 mg, 2.0 mg/mL, 10.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution
Graft-vs-Host Disease
, 10.0 mg, 2.0 mg/mL, 10.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution
Chronic Lymphocytic Leukemia
, 10.0 mg, 2.0 mg/mL, 10.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution
Hairy Cell Leukemia
, 10.0 mg, 2.0 mg/mL, 10.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution
Mycosis Fungoides
, 10.0 mg, 2.0 mg/mL, 10.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution
Prolymphocytic Leukemia
, 10.0 mg, 2.0 mg/mL, 10.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution

Warnings

There are 20 known major drug interactions with Pentostatin.
Common Pentostatin Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Pentostatin is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Pentostatin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Pentostatin is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Pentostatin is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Pentostatin is combined with Acteoside.
Pentostatin Toxicity & Overdose RiskThe lowest toxic dose of the drug for mice is 128mg/kg. Side effects of overdosing may include drowsiness, a rash, tiredness, nausea, and an impaired production of blood cells.

Pentostatin Novel Uses: Which Conditions Have a Clinical Trial Featuring Pentostatin?

206 active clinical trials are investigating the potential of Pentostatin to provide relief from Chronic Lymphocytic Leukemia, Graft-vs-Host Disease and Sezary Syndrome.
Condition
Clinical Trials
Trial Phases
Hairy Cell Leukemia
15 Actively Recruiting
Phase 2, Phase 1
Chronic Lymphocytic Leukemia
142 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4
Mycosis Fungoides
0 Actively Recruiting
Graft-vs-Host Disease
0 Actively Recruiting
Graft-vs-Host Disease
8 Actively Recruiting
Phase 3, Phase 2, Phase 1, Not Applicable
Sezary Syndrome
9 Actively Recruiting
Phase 2, Phase 1
Prolymphocytic Leukemia
10 Actively Recruiting
Phase 2, Not Applicable, Phase 1

Pentostatin Reviews: What are patients saying about Pentostatin?

1Patient Review
6/28/2008
Pentostatin for Progressive Chronic Lymphocytic Leukemia
My mother has cml and her doctor prescribed pentostatin, which costs $40,000. Her insurance won't help cover the cost. We're struggling to figure out how to pay for it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about pentostatin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What cyclophosphamide is used for?

"Cyclophosphamide is a drug used to treat various forms of cancer, including ovarian cancer, breast cancer, blood cancer, lymphatic cancer, and nervous system cancer (primarily in children). Cyclophosphamide is also used to treat retinoblastoma (a type of eye cancer that affects primarily children), multiple myeloma (a cancer of the bone marrow), and mycosis fungoides (a skin cancer)."

Answered by AI

Who makes pentostatin?

"Pentostatin is an anticancer drug that is manufactured by SuperGen."

Answered by AI

What are the side effects of pentostatin?

"The following are some potential side effects of the medication: feeling nauseous, vomiting, having diarrhea, loss of appetite, increased sweating, or mouth sores. If you experience any of these effects, speak to your doctor or pharmacist. There is a potential for serious side effects with this medication."

Answered by AI

How do you administer pentostatin?

"Pentostatin is a powder that is mixed with liquid and injected into a vein. It is usually injected once every other week."

Answered by AI

Clinical Trials for Pentostatin

Image of Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center in Cleveland, United States.

Rituximab + Tafasitamab + NK Cells for Non-Hodgkin's Lymphoma

18+
All Sexes
Cleveland, OH
This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. NK cells are an investigational (experimental) treatment which means they are not approved by the Food and Drug Administration (FDA). NK cells are a type of lymphocyte that's part of the body's natural immune system, and they can kill cancer cells by creating pores in the cancer cell membranes and inducing apoptosis (programmed cell death). Participants in this study will receive lymphodepleting chemotherapy, as well as Allogeneic NK cells, Tafasitamab and Interleukin-2 (IL-2) by an intravenous (IV) infusion. Participants are expected to complete one cycle, and they may be eligible to complete a second cycle of the same regiment if they have stable disease, partial or complete remission at the end of the first cycle. Participants will be in this study for about 12 months.
Phase 1
Waitlist Available
Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center (+1 Sites)Paolo Caimi, MDIncyte Corporation
Image of City of Hope Medical Center in Duarte, United States.

Venetoclax + Obinutuzumab + Epcoritamab for Chronic Lymphocytic Leukemia

18+
All Sexes
Duarte, CA
This phase II trial tests the effect of venetoclax and obinutuzumab followed by epcoritamab in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that have not previously received treatment. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Obinutuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Epcoritamab, a bispecific monoclonal antibody, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. The combination of venetoclax and obinutuzumab is a standard treatment for CLL/SLL and has been found to be safe and effective. Adding epcoritamab to standard treatment with venetoclax and obinutuzumab may lead to deeper and longer-lasting responses in patients with untreated CLL/SLL.
Phase 2
Waitlist Available
City of Hope Medical Center (+6 Sites)Alexey V Danilov
Have you considered Pentostatin clinical trials? We made a collection of clinical trials featuring Pentostatin, we think they might fit your search criteria.Go to Trials
Image of City of Hope Medical Center in Duarte, United States.

CMV-MVA Triplex Vaccine for Cancer

18 - 75
All Sexes
Duarte, CA
This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT. Significant CMV infection is associated with an increased risk of complications and death. Vaccination is the main preventative approach to limit complications and death in immunocompromised patients at high risk of post-stem cell transplant infections. CMV-MVA Triplex vaccine, is a CMV vaccine based on the attenuated poxvirus, modified vaccinia Ankara (MVA), developed to enhance CMV-specific immunity in both healthy stem cell transplant donors and stem cell transplant patients to prevent significant CMV infection post-stem cell transplant. Giving CMV-MVA triplex vaccine may be safe, tolerable and/or effective in enhancing cytomegalovirus (CMV)-specific immunity and preventing CMV viremia in patients undergoing a haploHCT.
Phase 1
Waitlist Available
City of Hope Medical Center (+2 Sites)Ryotaro Nakamura
Have you considered Pentostatin clinical trials? We made a collection of clinical trials featuring Pentostatin, we think they might fit your search criteria.Go to Trials
Image of Ohio State University Comprehensive Cancer Center LAO in Columbus, United States.

Tovorafenib + Rituximab for Hairy Cell Leukemia

18+
All Sexes
Columbus, OH
This phase I/II trial tests the safety, side effects, and effectiveness of tovorafenib in combination with rituximab in patients with classical hairy cell leukemia (cHCL) that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory) and compares the effect of tovorafenib and rituximab to current standard treatment of cladribine and rituximab in cHCL patients that have not yet received treatment. Tovorafenib blocks certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Cladribine damages the cell's deoxyribonucleic acid and may kill cancer cells. It is a type of antimetabolite. Giving tovorafenib in combination with rituximab may be safe and tolerable and more effective than cladribine with rituximab in treating patients with untreated, recurrent or refractory cHCL.
Phase 1 & 2
Recruiting
Ohio State University Comprehensive Cancer Center LAOSeema A Bhat
Have you considered Pentostatin clinical trials? We made a collection of clinical trials featuring Pentostatin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security